Shares in Amgen (NSDQ:AMGN) fell today even though the biotech topped expectations on Wall Street with its second quarter results.
The Thousand Oaks, Calif.-based company posted profits of $2.2 million, or $2.91 per share, on sales of $5.8 billion for the 3 months ended June 30, for bottom-line growth of 15% on sales growth of 2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Amgen shares fall after Q2 earnings reveal ‘bare’ pipeline appeared first on MassDevice.
from MassDevice http://ift.tt/2h3fq8E
Cap comentari:
Publica un comentari a l'entrada